Tags

Type your tag names separated by a space and hit enter

Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
Scand J Rheumatol 2008 Nov-Dec; 37(6):439-44SJ

Abstract

OBJECTIVE

To evaluate the importance of receptor activator of nuclear factor kappaB (RANK)/receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) modulation in active polyarticular juvenile idiopathic arthritis (pJIA) patients with and without bone erosions.

METHODS

Thirty female patients (mean age 11.07+/-3.77 years, range 4-17 years) with active pJIA and 30 healthy gender- and age-matched controls were consecutively selected for this study. All involved articulations were assessed by X-ray and examined for the presence of bone erosions. The serum levels of RANKL and OPG were measured using an enzyme-linked immunosorbent assay (ELISA).

RESULTS

Patients with active pJIA had higher levels of serum RANKL than controls [2.90 (0.1-37.4) vs. 0.25 (0.1-5.7) pg/mL, p = 0.007] and a lower OPG/RANKL ratio [21.25 (1.8-897.6) vs. 347.5 (9-947.8), p = 0.005]. However, levels of OPG were comparable in both groups [55.24 (28.34-89.76) vs. 64.42 (30.68-111.28) pg/mL, p = 0.255]. Higher levels of serum RANKL and a lower OPG/RANKL ratio were also observed in active pJIA patients with bone erosions compared to controls [3.49 (0.1-37.4) vs. 0.25 (0.1-5.7) pg/mL, p = 0.0115 and 14.3 (1.8-897.6) vs. 347.5 (9-947.8), p = 0.016]. However, RANKL levels and OPG/RANKL ratio were similar in pJIA patients without bone erosion and controls [1.75 (0.1-10.9) vs. 0.25 (0.1-5.7) pg/mL, p = 0.055 and 29.2 (3.3-756.8) vs. 347.5 (9-947.8), p = 0.281].

CONCLUSION

These data suggest that active pJIA with bone erosions is associated with high serum levels of RANKL and a low OPG/RANKL ratio, indicating that these alterations may reflect bone damage in this disease.

Authors+Show Affiliations

Paediatric Rheumatology Division, Hospital Evangelico de Curitiba, Paraná, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18802807

Citation

Spelling, P, et al. "Osteoprotegerin/RANKL System Imbalance in Active Polyarticular-onset Juvenile Idiopathic Arthritis: a Bone Damage Biomarker?" Scandinavian Journal of Rheumatology, vol. 37, no. 6, 2008, pp. 439-44.
Spelling P, Bonfá E, Caparbo VF, et al. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? Scand J Rheumatol. 2008;37(6):439-44.
Spelling, P., Bonfá, E., Caparbo, V. F., & Pereira, R. M. (2008). Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? Scandinavian Journal of Rheumatology, 37(6), pp. 439-44. doi:10.1080/03009740802116224.
Spelling P, et al. Osteoprotegerin/RANKL System Imbalance in Active Polyarticular-onset Juvenile Idiopathic Arthritis: a Bone Damage Biomarker. Scand J Rheumatol. 2008;37(6):439-44. PubMed PMID: 18802807.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker? AU - Spelling,P, AU - Bonfá,E, AU - Caparbo,V F, AU - Pereira,R M R, PY - 2008/9/20/pubmed PY - 2008/12/17/medline PY - 2008/9/20/entrez SP - 439 EP - 44 JF - Scandinavian journal of rheumatology JO - Scand. J. Rheumatol. VL - 37 IS - 6 N2 - OBJECTIVE: To evaluate the importance of receptor activator of nuclear factor kappaB (RANK)/receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) modulation in active polyarticular juvenile idiopathic arthritis (pJIA) patients with and without bone erosions. METHODS: Thirty female patients (mean age 11.07+/-3.77 years, range 4-17 years) with active pJIA and 30 healthy gender- and age-matched controls were consecutively selected for this study. All involved articulations were assessed by X-ray and examined for the presence of bone erosions. The serum levels of RANKL and OPG were measured using an enzyme-linked immunosorbent assay (ELISA). RESULTS: Patients with active pJIA had higher levels of serum RANKL than controls [2.90 (0.1-37.4) vs. 0.25 (0.1-5.7) pg/mL, p = 0.007] and a lower OPG/RANKL ratio [21.25 (1.8-897.6) vs. 347.5 (9-947.8), p = 0.005]. However, levels of OPG were comparable in both groups [55.24 (28.34-89.76) vs. 64.42 (30.68-111.28) pg/mL, p = 0.255]. Higher levels of serum RANKL and a lower OPG/RANKL ratio were also observed in active pJIA patients with bone erosions compared to controls [3.49 (0.1-37.4) vs. 0.25 (0.1-5.7) pg/mL, p = 0.0115 and 14.3 (1.8-897.6) vs. 347.5 (9-947.8), p = 0.016]. However, RANKL levels and OPG/RANKL ratio were similar in pJIA patients without bone erosion and controls [1.75 (0.1-10.9) vs. 0.25 (0.1-5.7) pg/mL, p = 0.055 and 29.2 (3.3-756.8) vs. 347.5 (9-947.8), p = 0.281]. CONCLUSION: These data suggest that active pJIA with bone erosions is associated with high serum levels of RANKL and a low OPG/RANKL ratio, indicating that these alterations may reflect bone damage in this disease. SN - 1502-7732 UR - https://www.unboundmedicine.com/medline/citation/18802807/Osteoprotegerin/RANKL_system_imbalance_in_active_polyarticular_onset_juvenile_idiopathic_arthritis:_a_bone_damage_biomarker L2 - http://www.tandfonline.com/doi/full/10.1080/03009740802116224 DB - PRIME DP - Unbound Medicine ER -